16.11.2015 • NewsElaine BurridgeAsia-PacificBASF

BASF Expands R&D Capabilities in Asia

German major BASF has officially opened an innovation center in China, expanding the scope of its R&D capabilities in Asia-Pacific. The Innovation Campus Asia-Pacific (Shanghai) in Pudong, which was inaugurated earlier this month, is BASF’s largest R&D center in the region. It is focused primarily on advanced materials and systems and adds capabilities including formulations and chemical processes and engineering.

The facility, which cost €90 million, also includes production and marketing functions and serves, said BASF, as an integrated platform to create innovations and applications together with customers. “The new facilities will enable BASF to better serve growth industries such as automotive, construction, health and nutrition, and home and personal care in the region,” said Sanjeev Gandhi, member of BASF’s board of executive directors and responsible for Asia-Pacific. He added that a design center would also be established to combine competencies in design-related materials and services.

Additionally, the headquarters of BASF’s Advanced Materials & Systems Research will be established at the Shanghai campus as of Jan. 1 2016. Its president, Harald Lauke, will assume responsibility as BASF’s regional research representative for the Asia-Pacific region.

The company is also spending around €50 million to build a new innovation campus in Navi Mumbai, India, which is planned to go into operation in 2017. This facility will accommodate around 300 scientists researching areas such as crop protection, process development and polymer research.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.